BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Berahovich R, Liu X, Zhou H, Tsadik E, Xu S, Golubovskaya V, Wu L. Hypoxia Selectively Impairs CAR-T Cells In Vitro. Cancers (Basel) 2019;11:E602. [PMID: 31052261 DOI: 10.3390/cancers11050602] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 . Editor's Pick: Tumour-Associated Hypoxia: Can We Give Chimeric Antigen Receptor T Cells More Breathing Space? EMJ. [DOI: 10.33590/emj/20-00076] [Reference Citation Analysis]
2 Gao TA, Chen YY. Engineering Next-Generation CAR-T Cells: Overcoming Tumor Hypoxia and Metabolism. Annu Rev Chem Biomol Eng 2022;13:193-216. [PMID: 35700528 DOI: 10.1146/annurev-chembioeng-092120-092914] [Reference Citation Analysis]
3 Ghilardi G, Braendstrup P, Chong EA, Schuster SJ, Svoboda J, Ruella M. CAR-T TREK through the lymphoma universe, to boldly go where no other therapy has gone before. Br J Haematol 2021;193:449-65. [PMID: 33222167 DOI: 10.1111/bjh.17191] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Salinas RD, Durgin JS, O'Rourke DM. Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy. CNS Drugs 2020;34:127-45. [PMID: 31916100 DOI: 10.1007/s40263-019-00687-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
5 Nguyen DT, Ogando-Rivas E, Liu R, Wang T, Rubin J, Jin L, Tao H, Sawyer WW, Mendez-Gomez HR, Cascio M, Mitchell DA, Huang J, Sawyer WG, Sayour EJ, Castillo P. CAR T Cell Locomotion in Solid Tumor Microenvironment. Cells 2022;11:1974. [PMID: 35741103 DOI: 10.3390/cells11121974] [Reference Citation Analysis]
6 Zhao Z, Xiao X, Saw PE, Wu W, Huang H, Chen J, Nie Y. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment. Sci China Life Sci 2020;63:180-205. [PMID: 31883066 DOI: 10.1007/s11427-019-9665-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
7 Pellegrino M, Del Bufalo F, De Angelis B, Quintarelli C, Caruana I, de Billy E. Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy. Cells 2020;10:E14. [PMID: 33374128 DOI: 10.3390/cells10010014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. Addressing the obstacles of CAR T cell migration in solid tumors: wishing a heavy traffic. Crit Rev Biotechnol 2021;:1-20. [PMID: 34957875 DOI: 10.1080/07388551.2021.1988509] [Reference Citation Analysis]
9 Liu A, Curran MA. Tumor hypermetabolism confers resistance to immunotherapy. Semin Cancer Biol 2020;65:155-63. [PMID: 31982512 DOI: 10.1016/j.semcancer.2020.01.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
10 Sureban SM, Berahovich R, Zhou H, Xu S, Wu L, Ding K, May R, Qu D, Bannerman-Menson E, Golubovskaya V, Houchen CW. DCLK1 Monoclonal Antibody-Based CAR-T Cells as a Novel Treatment Strategy against Human Colorectal Cancers. Cancers (Basel) 2019;12:E54. [PMID: 31878090 DOI: 10.3390/cancers12010054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
11 Ando Y, Mariano C, Shen K. Engineered in vitro tumor models for cell-based immunotherapy. Acta Biomater 2021;132:345-59. [PMID: 33857692 DOI: 10.1016/j.actbio.2021.03.076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Kim GB, Riley JL, Levine BL. Engineering T cells to survive and thrive in the hostile tumor microenvironment. Current Opinion in Biomedical Engineering 2022;21:100360. [DOI: 10.1016/j.cobme.2021.100360] [Reference Citation Analysis]
13 Rodriguez-Garcia A, Palazon A, Noguera-Ortega E, Powell DJ Jr, Guedan S. CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape. Front Immunol 2020;11:1109. [PMID: 32625204 DOI: 10.3389/fimmu.2020.01109] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 19.5] [Reference Citation Analysis]
14 Chinn HK, Gardell JL, Matsumoto LR, Labadie KP, Mihailovic TN, Lieberman NAP, Davis A, Pillarisetty VG, Crane CA. Hypoxia-inducible lentiviral gene expression in engineered human macrophages. J Immunother Cancer 2022;10:e003770. [PMID: 35728871 DOI: 10.1136/jitc-2021-003770] [Reference Citation Analysis]
15 Newport EL, Pedrosa AR, Njegic A, Hodivala-Dilke KM, Muñoz-Félix JM. Improved Immunotherapy Efficacy by Vascular Modulation. Cancers (Basel) 2021;13:5207. [PMID: 34680355 DOI: 10.3390/cancers13205207] [Reference Citation Analysis]
16 Hauth F, Ho AY, Ferrone S, Duda DG. Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review. JAMA Oncol 2021;7:1051-9. [PMID: 33885725 DOI: 10.1001/jamaoncol.2021.0168] [Reference Citation Analysis]
17 Li T, Li H, Li S, Xu S, Zhang W, Gao H, Xu H, Wu C, Wang W, Yu X, Liu L. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma. Cancer Med 2019;8:5223-31. [PMID: 31339230 DOI: 10.1002/cam4.2430] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
18 Gamboa L, Zamat AH, Kwong GA. Synthetic immunity by remote control. Theranostics 2020;10:3652-67. [PMID: 32206114 DOI: 10.7150/thno.41305] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
19 Armitage JD, Newnes HV, McDonnell A, Bosco A, Waithman J. Fine-Tuning the Tumour Microenvironment: Current Perspectives on the Mechanisms of Tumour Immunosuppression. Cells 2021;10:E56. [PMID: 33401460 DOI: 10.3390/cells10010056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Wu L, Huang Y, Sienkiewicz J, Sun J, Guiang L, Li F, Yang L, Golubovskaya V. Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth. Cancers 2022;14:2518. [DOI: 10.3390/cancers14102518] [Reference Citation Analysis]
21 Kopecka J, Salaroglio IC, Perez-Ruiz E, Sarmento-Ribeiro AB, Saponara S, De Las Rivas J, Riganti C. Hypoxia as a driver of resistance to immunotherapy. Drug Resist Updat 2021;:100787. [PMID: 34840068 DOI: 10.1016/j.drup.2021.100787] [Reference Citation Analysis]
22 Amini A, Wiegmann V, Patel H, Veraitch F, Baganz F. Bioprocess considerations for T-cell therapy: Investigating the impact of agitation, dissolved oxygen, and pH on T-cell expansion and differentiation. Biotechnol Bioeng 2020;117:3018-28. [PMID: 32568407 DOI: 10.1002/bit.27468] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Miao L, Zhang Z, Ren Z, Tang F, Li Y. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors. Front Immunol 2021;12:687822. [PMID: 34093592 DOI: 10.3389/fimmu.2021.687822] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Lappano R, Todd LA, Stanic M, Cai Q, Maggiolini M, Marincola F, Pietrobon V. Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment. Cancers 2022;14:539. [DOI: 10.3390/cancers14030539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Guo F, Cui J. CAR-T in solid tumors: Blazing a new trail through the brambles. Life Sciences 2020;260:118300. [DOI: 10.1016/j.lfs.2020.118300] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
26 Guo F, Cui J. CAR-T in Cancer Treatment: Develop in Self-Optimization, Win-Win in Cooperation. Cancers (Basel) 2021;13:1955. [PMID: 33921581 DOI: 10.3390/cancers13081955] [Reference Citation Analysis]
27 Kennedy PR, Felices M, Miller JS. Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer. Stem Cell Res Ther 2022;13:165. [PMID: 35414042 DOI: 10.1186/s13287-022-02769-4] [Reference Citation Analysis]
28 Wang Y, Qiu F, Xu Y, Hou X, Zhang Z, Huang L, Wang H, Xing H, Wu S. Stem cell-like memory T cells: The generation and application. J Leukoc Biol 2021. [PMID: 34402104 DOI: 10.1002/JLB.5MR0321-145R] [Reference Citation Analysis]
29 Roex G, Timmers M, Wouters K, Campillo-Davo D, Flumens D, Schroyens W, Chu Y, Berneman ZN, Lion E, Luo F, Anguille S. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J Hematol Oncol 2020;13:164. [PMID: 33272302 DOI: 10.1186/s13045-020-01001-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
30 Khorasani ABS, Sanaei MJ, Pourbagheri-Sigaroodi A, Ghaffari SH, Bashash D. CAR T cell therapy in solid tumors; with an extensive focus on obstacles and strategies to overcome the challenges. Int Immunopharmacol 2021;101:108260. [PMID: 34678690 DOI: 10.1016/j.intimp.2021.108260] [Reference Citation Analysis]